GH Research PLC (GHRS) News
Track canonical SquawkNews coverage tagged to GHRS, GH Research PLC. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 7 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
FDA holds public hearing on psychedelic drugs as Trump-driven push gathers pace
By Puyaan Singh and Kamal ChoudhuryThe U.S. FDA is holding a public hearing on Monday to gather feedback on the potential therapeutic use of psychedelic drugs, the latest step in a months-long push by President Donald Tr
REGULATION | Sep 14, 2026, 07:30 PM UTC
L
GHRS - GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
GHRS - GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 06, 2026, 11:02 AM UTC
L
GHRS Initiated Overweight W/$44.00 PT at Wells Fargo
GHRS Initiated Overweight W/$44.00 PT at Wells Fargo
EQUITY | Jul 27, 2026, 12:08 PM UTC
L
Peer GHRS +14% premarket after ATAI M&A headlines
Peer GHRS +14% premarket after ATAI M&A headlines
MNA | Jul 16, 2026, 11:15 AM UTC
H
FDA announces availability of final guidance for psychedelic drug research
The agency said,...
EARNINGS | Jul 15, 2026, 03:12 PM UTC
H
Jefferies says guidance suggests FDA receptive to helping psychedelic sponsors
Jefferies notes that on...
EQUITY | Jul 13, 2026, 05:12 PM UTC
H
CMPS: Depression Drug 86% Through Phase 3
CMPS' breakthrough-designated depression drug is 86% through its Phase 3 with topline data due this year
EQUITY | Jun 26, 2026, 01:31 PM UTC